Comparison of Somatostatin Receptor Agonist and Antagonist for Peptide Receptor Radionuclide Therapy: A Pilot Study-Reference-Cited by-同舟云学术

Comparison of Somatostatin Receptor Agonist and Antagonist for Peptide Receptor Radionuclide Therapy: A Pilot Study

Published:2014-06-24 Issue:8 Volume:55 Page:1248-1252
ISSN:0161-5505
Container-title:Journal of Nuclear Medicine
language:en
Short-container-title:J Nucl Med

Author:

Wild Damian,Fani Melpomeni,Fischer Richard,Del Pozzo Luigi,Kaul Felix,Krebs Simone,Fischer Richard,Rivier Jean E.F.,Reubi Jean Claude,Maecke Helmut R.,Weber Wolfgang A.

Publisher

Society of Nuclear Medicine

Subject

Radiology, Nuclear Medicine and imaging

Reference10 articles.

1. Peptide-receptor radionuclide therapy for endocrine tumors

2. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors

3. Evaluation of 177Lu-DOTA-sst2 Antagonist Versus 177Lu-DOTA-sst2 Agonist Binding in Human Cancers In Vitro

4. First Clinical Evidence That Imaging with Somatostatin Receptor Antagonists Is Feasible

5. Unexpected Sensitivity of sst2 Antagonists to N-Terminal Radiometal Modifications

Cited by 201 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PET imaging of [ 52 Mn]Mn-DOTATATE and [ 52 Mn]Mn-DOTA-JR11;2024-08-09

2. Structure and Function of Somatostatin and Its Receptors in Endocrinology;Endocrine Reviews;2024-08-08

3. Von der PET-Bildgebung zur Theranostik – nuklearmedizinische Perspektiven beim kleinzelligen Lungenkarzinom;Die Onkologie;2024-07-15

4. Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: Agonist, Antagonist and Alternatives;Seminars in Nuclear Medicine;2024-07

5. Recent advances and future challenges in the diagnosis of neuroendocrine neoplasms;Minerva Endocrinology;2024-07